Tag Archives: pharmaceuticals

DBruggeman

CRA President Receives Stevie Awards

David M. Bruggeman, President and Chief Operating Officer of Clinical Research Advantage, Inc. (CRA), was the recipient of two Stevie Awards at the 11th annual American Business Awards. Bruggeman received the Bronze Award for “Executive of the Year” in both the Pharmaceuticals and Health Products and Services categories.

Bruggeman was recognized for his ingenuity and leadership in building the country’s largest integrated network of clinical trial sites and partnering with Quintiles to create the first-ever therapeutic alliance for clinical trials in primary medicine. “David is an extraordinary leader whose work has improved the quality and efficiency of the clinical research process,” said Mark S. Hanley, CRA’s Chief Executive Officer. “We are happy to hear that David has received this national honor.”

The American Business Awards are the nation’s premier business awards program. All organizations operating in the U.S.A. are eligible to submit nominations – public and private, for-profit and non-profit, large and small. Stevie Award winners were selected by more than 320 executives nationwide who participated in the judging process this year.

Nicknamed the Stevies for the Greek word for “crowned,” the awards were held on June 17th in Chicago, Illinois. This year, the judges reviewed more than 3,200 nominations from organizations of all sizes and virtually every industry.

Funding Startup Companies Jumpstart Economy

GPEC boosts state’s economy by attracting more foreign direct investment

The Greater Phoenix Economic Council’s California 50 program — which aimed to fly 50 Golden State CEOs to Phoenix for an opportunity to tour and explore the region’s business-friendly environment — proved to be so popular that they expanded it to 100 a week after its launch.

But it may be GPEC’s pitch to CEOs even farther away that makes the biggest impact on Arizona’s economy.

“GPEC is focused on a specific region in China, defined by Shanghai and 10 other cities connected by high-speed rail,” says Ron Butler, managing partner at Ernst & Young in Phoenix and co-chair of GPEC’s International Leadership Council. “This region (known as the ‘Z Corridor’) features China’s largest concentration of industries, including solar, medical device, IT, pharmaceuticals, high-tech manufacturing and chemicals. GPEC has made tremendous strides over the past several years in China, particularly with solar and renewable energy companies. Now, the organization is looking to leverage those relationships and expand into other, capital-intensive industries.”

GPEC’s effort is significant, Butler says, because export industries and foreign direct investment (FDI) drive economic growth, create wealth within the region, and tend to be capital-intensive operations that pay higher-than-average wages. Currently, FDI accounts for 73,000 jobs in Arizona and the state saw a 235 percent increase in FDI from 2005-2010, from just over $270 million to more than $904 million.

“By focusing on the Z corridor, a zone known for its solar, high-tech, bio-medical, and chemical industries, GPEC has identified a region that can appreciate what Arizona and — more importantly Arizona workers — can do well,” says Ilya A. Iussa, assistant professor of law at Phoenix School of Law.

But it’s not just investment from China that is giving Arizona an economic boost within the solar and renewable energy industries. In addition to China’s Suntech, the region has seen investments from Spain’s Rioglass and Abengoa, England’s Faist, Germany’s Solon, France’s Saint-Gobain, and Canada’s Cosma International.

“GPEC smartly targets the regions and countries that represent significant growth opportunities, like Canada, China and Western Europe, and works these markets with effective marketing and business development strategies,” Butler says. “Now, with a more concentrated effort underway in China and successful positioning as both a leader in the U.S. solar market and an on-the-record supporter of expanded free trade with China, the Greater Phoenix region is poised for amplified growth in FDI, particularly from China.”

Despite its success, experts says Arizona still has some work to do.

“Our neighboring states and biggest competitors far outrank us in national FDI and export-trade rankings,” Butler says. “California is first for FDI and second for exports, while Texas is second for FDI and first for exports. As such, we must continue evaluating our market for additional FDI and export industry opportunities, and look for ways to increase our competitiveness in these areas.”

Lawmakers have identified one area that needs to be addressed to gain a competitive edge on other states.

“One of the first things we should do is focus on developing a highly educated workforce that will attract companies and businesses looking to move their headquarters,” says Rep. Matt Salmon, R-5. “In addition, it is equally important for us to create a pro-business environment and that comes by reducing harmful regulations that hamper economic growth. Both would increase Arizona’s role in the global economy.”

In order to be increase its global presence and become more competitive with neighboring states like California and Texas, Butler says Arizona must increase the number of export industries operating in the state.

“We can increase our competitiveness for these types of investments,” he says, “with a targeted economic development program for export industries, similar to the Renewable Energy Tax Incentive Program (SB1403), which has brought significant investments to the region and the Qualified Facilities Tax Credit (HB2815), which expanded the successful renewable energy program to include qualified, export-based investments.”

clinical research advantage - vaccines

Clinical Research Advantage Earns Vaccine Industry Excellence Award

Tempe-based Clinical Research Advantage, a community-based network of clinical trial sites, has been named Best Clinical Trial Site Network by the World Vaccine Congress. The award was announced at the 2012 Vaccine Industry Excellence Awards in Washington, D.C. on April 11th. The VIE Awards celebrate the leaders, innovators and pioneers in the vaccine industry. Clinical Research Advantage also received second place for Best Clinical Trial Site.

“We are honored to win this prestigious award,” said Mark Hanley, CEO of Clinical Research Advantage. “The key to CRA’s success has been the development of research offices within community physician practices. We take pride in partnering with these established practices to provide rapid, successful enrollment that expedites the process of bringing vaccines to market.”

Casey Orvin, CRA’s Vice President of Business Development was on hand to accept the award in Washington, D.C. “It is with great honor that we accept the award for Best Clinical Trial Site Network. We are grateful to all the pharmaceutical sponsors and CROs who trust our sites and staff, time and time again, to successfully enroll in their vaccine studies. We have been fortunate, for the last several years, to be the leader in providing high quality data and rapidly enrolling sites to the vaccine industry,” said Orvin.

The Vaccine Industry Excellence Award nominees are voted on by an independent judging panel, comprised of senior industry representatives from public health organizations, non-governmental organizations, academic and research institutes, industry experts and affiliate member associations, pharmaceutical, biotech, global consultancies and press affiliates.

For more information on Clinical Research Advantage, visit Clinical Research Advantage’s website at crastudies.com.